Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that primarily inhibits vascular endothelial growth factor receptor-1, -2 and -3, platelet endothelial growth factor receptor-α, and -β, and the stem-cell factor receptor c-kit. In preliminary experiments using angiogenesis models with mice and rabbits, pazopanib inhibited angiogenesis caused by combined vascular endothelial growth factor and basic fibroblast growth factor. Although pazopanib was developed as a therapeutic agent against various tumors, it is currently approved in many countries for advanced soft-tissue sarcoma and renal cell carcinoma. The importance of pazopanib has been acknowledged, with positive results demonstrated in large-scale clinical trials involving patients with soft-tissue sarcoma and renal cell carcinoma. However, adverse events such as liver dysfunction and hypertension are common, often necessitating treatment discontinuation. These adverse events are generally manageable, and from the perspective of health-related quality of life and cost-effectiveness, pazopanib provides an improvement in quality-adjusted life years and decreases the treatment cost compared with other alternatives. In this review, we present the results of clinical trials and discuss the pharmacological action of pazopanib, with the aim of evaluating its current state by examining various associated issues.
26 December 2019 in Clinical and Experimental Nephrology
We retrospectively compared the post‐transplantation graft survival and the donor’s estimated glomerular filtration rates (eGFRs) following living donor kidney transplantations (LDKTs) involving medically complex living donors (MCLDs) (the elderly and patients with obesity, hypertension, diabetes mellitus, or reduced renal function) and standard living donors (SLDs). The clinical data on patients who underwent LDKTs at our institution from 2006–2019, including 192 SLDs and 99 MCLDs, were evaluated. Regarding recipients, the log‐rank test and multivariable Cox proportional hazards analyses showed a higher incidence of overall and death‐censored graft loss in the recipients who received kidneys from MCLDs (Hazard ratio = 2.16 and 3.25, p = 0.015 and 0.004, respectively), after adjusting for recipient‐related variables including age, sex, duration of dialysis, ABO compatibility, and donor‐specific antibody positivity. Regarding donors, a linear mixed model showed significantly lower post‐donation eGFRs (‐2.25 mL/min/1.73m2, p = 0.048) at baseline in MCLDs than SLDs, but comparable change (difference = 0.01 mL/min/1.73m2/year, p = 0.97). In conclusion, although kidneys from MCLDs are associated with impaired graft survival, the donation did not adversely affect the MCLDs’ renal health in at least the short‐term. LDKTs involving carefully selected MCLDs would be an acceptable alternative for recipients with no SLDs.
11 October 2021 in International Journal of Urology
Kidney xenotransplantation has been attracting attention as a treatment option for end-stage renal disease. Fetal porcine kidneys are particularly promising grafts because they can reduce rejection through vascularization from host vessels. We are proposing xenogeneic regenerative medicine using fetal porcine kidneys injected with human nephron progenitor cells. For clinical application, it is desirable to establish reliable methods for the preservation and quality assessment of grafts. We evaluated the differentiation potency of vitrified porcine fetal kidneys compared with nonfrozen kidneys, using an in vivo differentiation model. Fetal porcine kidneys connected to the bladder were frozen via vitrification and stored in liquid nitrogen. Several days later, they were thawed and transplanted under the retroperitoneum of immunocompromised mice. After 14 days, the frozen kidneys grew and differentiated into mature nephrons, and the findings were comparable to those of nonfrozen kidneys. In conclusion, we demonstrated that the differentiation potency of vitrified fetal porcine kidneys could be evaluated using this model, thereby providing a practical protocol to assess the quality of individual lots.
Novel transplantable organs need to be developed to address the global organ shortage. Transplantation of embryonic kidney tissue, or metanephros, facilitates glomerular and tubular maturation and offers partial organ functional support. However, adult environments do not permit exponential growth in size, limiting the life-supporting functionality and organ replacement effect of this approach. Here, we developed a novel strategy that combines the fusion of embryonic bladders with multiple anastomoses to the host ureter, enabling a significant increase in metanephros transplantation and urinary tract integration. By surgically anastomosing divided bladder segments, we reconstructed the excretory pathways by merging four metanephroi into each bladder and integrating them with the host ureter. Following the transplantation and integration of 20 metanephroi at the para-aortic region, anephric rats survived for over a month and generated approximately 50,000 nephrons in vivo. Ultrastructural and single-cell-transcriptomic analyses revealed that the maturity of the transplanted metanephroi was comparable to that of adult kidneys, although their small size likely contributed to their decreased urine concentration ability. Postoperative support helped normalize physiological homeostasis, including solute clearance, acid-base balance, electrolyte levels, and kidney hormone levels, within vital ranges. Our findings underscore the functional maturation capacity and dose-dependent therapeutic efficacy of embryonic kidney tissue, suggesting its potential as a transplantable organ system.